Patent application number | Description | Published |
20110239888 | REACTIVE SHAPED CHARGE, REACTIVE LINER, AND METHOD FOR TARGET PENETRATION USING A REACTIVE SHAPED CHARGE - Embodiments of a reactive shaped charge, a reactive liner, and a method for penetrating a target are generally described herein. The reactive shaped charge comprises a reactive liner having a matrix of reactive metal particles in a hydrocarbon fuel, a high explosive, and an inner barrier separating the reactive liner from the high explosive. The hydrocarbon fuel fills the interstitial spacing between the reactive metal particles, and the matrix is tightly packed or compresses to exhibit a solid like property. | 10-06-2011 |
20120024180 | REACTIVE SHAPED CHARGE, REACTIVE LINER, AND METHOD FOR TARGET PENETRATION USING A REACTIVE SHAPED CHARGE - Embodiments of a reactive shaped charge, a reactive liner, and a method for penetrating a target are generally described herein. The reactive shaped charge comprises a reactive liner having a matrix of reactive metal particles in a hydrocarbon fuel, a high explosive, and an inner barrier separating the reactive liner from the high explosive. The hydrocarbon fuel fills the interstitial spacing between the reactive metal particles, and the matrix is tightly packed or compresses to exhibit a solid like property. | 02-02-2012 |
Patent application number | Description | Published |
20090087426 | Methods for Treatment of Allergic Asthma - Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described. | 04-02-2009 |
20090280129 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 11-12-2009 |
20100158898 | METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS - The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. | 06-24-2010 |
20110311520 | METHODS FOR TREATMENT OF ALLERGIC ASTHMA - Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described. | 12-22-2011 |
20120064086 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 03-15-2012 |
20120076783 | REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. | 03-29-2012 |
20150044198 | REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. | 02-12-2015 |